skip to main content

United Therapeutics Corporation Completes Acquisition Of SteadyMed Ltd.

Download PDF Version

SILVER SPRING, Md., Aug. 30, 2018 /PRNewswire/ -- United Therapeutics Corporation (NASDAQ: UTHR) ("United Therapeutics") today announced that it has closed the merger of SteadyMed Ltd. (NASDAQ: STDY) ("SteadyMed") with a subsidiary of United Therapeutics. Pursuant to the merger, United Therapeutics acquired all of the outstanding ordinary shares of SteadyMed. As a result of the merger, SteadyMed ordinary shares are no longer publicly traded on the NASDAQ Stock Market.

About United Therapeutics

United Therapeutics is a biotechnology company focused on the development and commercialization of innovative products to address the unmet medical needs of patients with chronic and life-threatening conditions. [uthr-g]

Cision View original content:http://www.prnewswire.com/news-releases/united-therapeutics-corporation-completes-acquisition-of-steadymed-ltd-300704754.html

SOURCE United Therapeutics Corporation

Recent Press Releases

29 Jul 2026

United Therapeutics Corporation Announces ADVANCE OUTCOMES Study of Ralinepag Published in The Lancet
The long-term, pivotal, phase 3 ADVANCE OUTCOMES study of ralinepag in predominantly pre-treated patients with pulmonary arterial hypertension (PAH) met its primary endpoint and important secondary endpoints with...
Download pdf

23 Jul 2026

United Therapeutics Corporation Announces Appointment of Victor Dzau to its Board of Directors
SILVER SPRING, Md. & DURHAM, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, announced today that the company’s Board of Directors appointed Victor Dzau...
Download pdf

22 Jul 2026

United Therapeutics Corporation to Report Second Quarter 2026 Financial Results Before Market Open on Wednesday, August 5, 2026
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR) announced today that it will report its second quarter 2026 financial results in a press release...
Download pdf

02 Jul 2026

United Therapeutics Corporation Acquires Thymmune Therapeutics
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR) announced today it has acquired Thymmune Therapeutics, Inc. (Thymmune), a privately held...
Download pdf

29 Jun 2026

United Therapeutics Corporation Announces FDA Approval of the LungFX™ Device for Centralized Ex Vivo Lung Perfusion
LungFX™ is the first device approved for centralized ex vivo lung perfusion for donor organs not otherwise used for transplant, an important step in advancing United Therapeutics’ platformsSILVER SPRING, Md. &...
Download pdf

27 May 2026

United Therapeutics Corporation to Present at the Jefferies Global Healthcare Conference
SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- United Therapeutics Corporation (Nasdaq: UTHR) announced today that James Edgemond,Chief Financial Officer and Treasurer, will provide a company...
Download pdf
view all